Compare HHS & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HHS | NSRX |
|---|---|---|
| Founded | 1923 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 37.1M |
| IPO Year | 1994 | 2024 |
| Metric | HHS | NSRX |
|---|---|---|
| Price | $3.70 | $3.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 39.2K | 23.0K |
| Earning Date | 11-09-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,570,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.00 | $1.98 |
| 52 Week High | $4.67 | $9.50 |
| Indicator | HHS | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 24.92 | 47.13 |
| Support Level | $3.40 | $2.90 |
| Resistance Level | $4.45 | $3.60 |
| Average True Range (ATR) | 0.16 | 0.25 |
| MACD | -0.10 | -0.03 |
| Stochastic Oscillator | 24.56 | 33.00 |
Harte-Hanks Inc is a customer experience company. The company operates three business segments: Revenue Solutions; Customer Care; and Fulfillment & Logistics Services. It derives maximum revenue from Fulfillment & Logistics Services segment. The Fulfillment & Logistics Services segment includes printing, lettershop, advanced mail optimization (including commingling services), logistics and transportation optimization, monitoring and tracking, to support traditional and specialized mailings. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.